Process optimization of mRNA purification for vaccines and therapeutic applications

Nucleic Acid Insights 2024; 1(8), 263–278

DOI: 10.18609/nai.2024.033

Published: 4 September
Innovator Insight
Chantelle Gaskin

Critical to bringing mRNA therapeutics to patients is an efficient, effective, and scalable downstream production process. This article explores the development, characterization, and optimization of an mRNA capture step using POROS™ Oligo (dT)25 Affinity Resin. This resin provides an affinity solution that leverages the rigid POROS backbone with its linear pressure-flow relationship, enabling a consistent purification platform from process development through to clinical manufacturing.